Indicated for the treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM)

The NovoTTF-100L System is the first FDA-approved treatment for MPM in over 15 years1-4

NovoTTF-100L and pemetrexed + cisplatin/carboplatin may help your patients with MPM live longer with no added chemotherapy-related side effects1

18.2 months - Primary endpoint - Median overall survival (OS) - (95% CI 12.1-25.8) across all patients treated with NovoTTF-100L and pemetrexed + cisplatin/carboplatin

NovoTTF-100L approval was based on the STELLAR trial: a phase II, prospective, pivotal, single-arm trial designed to study the safety and efficacy of NovoTTF-100L and pemetrexed + cisplatin/carboplatin first-line in patients with unresectable, locally advanced or metastatic, MPM.2

No systemic AEs were considered to be related to the use of NovoTTF-100L1

  • The only AE attributed to the use of NovoTTF-100L is the known skin irritation seen in 71% of patients in this study (66% mild to moderate and 5% severe)
Learn more about NovoTTF-100L™

NovoTTF-100L is designed to fit 
into your patients' daily lives

See how

 

Novocure® offers an award-winning support program

nCompassTM offers customized support based on patient and caregiver needs

 

Learn more about nCompass™

 

Helpful resources for you
and your patients

Explore resources

References: 1. NovoTTF-100L Instructions For Use for Unresectable Malignant Pleural Mesothelioma. Novocure 2019. 2. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. 3. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644.

Next: HDE approval for unresectable MPM
Back to top
Indications For Use
jump to isi

The NovoTTF-100L System is indicated for the treatment of adult patients with unresect…